We are delighted to welcome top-tier investors who have been part of recent French success stories (Mablink, Amolyt Pharma). This is an important milestone for Brenus Pharma, confirming the potential of the STC platform and of STC-1010, which has already demonstrated solid proof of efficacy in various preclinical models.
The French company will use the capital to fund the first-in-human proof-of-concept of the STC-1010 cancer vaccine in first-line settings for metastatic colorectal cancer patients.
Brenus Pharma has received non-dilutive funding from the French government and Bpifrance as a beneficiary of the France 2030 call for projects.
The STC-1010 vaccine is the first candidate based on the STC 'Stimulated-Tumor-(ghost)-Cells' technology platform developed by Brenus Pharma.
[
Collection
]
[
|
...
]